A Supplier’s Strategy for Elemental Testing and Risk Assessment

Katherine Ulman
Global Regulatory Compliance Manager
Dow Corning Corporation, a wholly owned subsidiary of The Dow Chemical Company
Overview

History of ICH Q3D and its implications for excipient suppliers

Understanding excipient sources, potential for elemental impurities/impurity variability and use of published data

Gathering relevant elemental impurity data

A case study for one excipient supplier’s strategy
History of ICH Q3D and its implications for excipient suppliers
ICH Q3D Overview from an excipient supplier perspective

A Requirement for Drug Manufacturers:
• Requires an assessment of the potential elemental impurities present in drug products.

ICH Q3D applies to:
• All human drug products - Emphasizes the use of risk assessment as opposed to testing wherever possible

Does not apply to:
• Components, i.e. drug substance/ excipients
• No compliance requirement for excipient suppliers other than to share what they may know and what they do not know about EI in their excipients – will often vary from supplier to supplier and possibly for different excipients from the same supplier!
ICH Q3D – Risk Assessment for potential sources of EI – need to assess excipients

ICH Q3D advocates a risk assessment approach to determine the level of elemental impurities in drug products and the risk posed to patients.

“The data that support the risk assessment can come from:

• Prior knowledge,
• Published literature,
• Information provided from suppliers
• Data generated from testing of components of the drug product,
• Data generated from testing the drug product”

USP – US Pharmacopeal Convention

The intention is to use testing to evaluate risk……not test every batch…..unless needed due to unpredictability

Trademark of The Dow Chemical Company (“DOW”) or an affiliated company of Dow.
ICH Q3D Workshop – FDA/OPF’s Perspective
Edwin Jao, Ph. D.
Acting Branch Chief FDA/CDER/OPQ/DIVIII/Branch VII

Risk Based Control Strategies

cGMP

- Qualification, usage, maintenance, cleaning of equipment, change control
- Quality agreement with vendors including auditing
- **The responsibility is on the drug product manufacturers**

Vendor provided compatibility information is always helpful; however, the applicability of the information is process and product dependent and therefore generally established by drug product manufacturer
### Q3D Table 5-1: Elements considered in the risk assessment

<table>
<thead>
<tr>
<th>Elements</th>
<th>Class</th>
<th>If Intentionally added</th>
<th>If not intentionally added</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Oral</td>
<td>Parenteral</td>
</tr>
<tr>
<td>Cd</td>
<td>1</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Pb</td>
<td>1</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>As</td>
<td>1</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Hg</td>
<td>1</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Co</td>
<td>2A</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>V</td>
<td>2A</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Ni</td>
<td>2A</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Ti</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Au</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Pd</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Ir</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Os</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Rh</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Ru</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Se</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Ag</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Pt</td>
<td>2B</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Li</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Sb</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Ba</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Mo</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Cu</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Sn</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Cr</td>
<td>3</td>
<td>YES</td>
<td>NO</td>
</tr>
</tbody>
</table>
Understanding excipient sources, potential for elemental impurities/impurity variability and use of published data
Potential sources of excipients

• Chemical synthesis
  – polymer mixtures derived through synthetic processes (colloidal SiO₂)
  – may use metal catalysts (e.g. povidone, PEG, silicones)

• Mined minerals
  – Conversion of ores from mines (e.g. TiO₂)
  – NOTE: Many metal impurities naturally present (e.g. lead) in mined excipients and cannot be further processed out; therefore, it is important to understand the actual levels present and expect normal variation and excursions which CANNOT be predicted!

• Harvested vegetation
  – Grown in soil (e.g. cellulose derivatives)
  – Harvested from the ocean (e.g. alginates, carrageenan)
  – Need understanding of source variability and level of processing in order to accurately predict EI levels – MORE THAN 3-6 batches!

• Formulated products
• Biotech & fermentation
• Genetic modification
• Animal by-products
  – lactose & gelatin
Potential elemental impurities from excipients

How to decide what potential levels of risk an excipient might have

Elemental Impurities in Excipients:
- Mined (e.g. Talc)
- Synthesized with Metal Catalyst (e.g. mannitol)
- Plant Origin (e.g. cellulose derivatives)
- Animal Origin (e.g. lactose & gelatin)
- Synthesised without Metal Catalyst (e.g. colloidal SiO₂)

Increasing potential risk of contributing elemental impurities

What does the evidence show?

®Trademark of The Dow Chemical Company ("DOW") or an affiliated company of Dow.
Unknowns - Analysis by FDA lab

IPEC Americas request for “blinded samples” to be tested by FDA lab

Q1 2012
Law office for IPEC – Americas collected, blinded and submitted excipient samples to FDA lab for analysis

Q2-Q4 2012
FDA analyzed samples using ICP-MS

Q1 2013
Law office un-blinded and sent results to original submitters.

2014
Study completed - Industry assessed FDA results vs industry results

Q1 2013
Additional samples sent to FDA

2014
Study completed - Industry assessed FDA results vs industry results

FDA & IPEC published data in journal - Fall 2015

RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology

Elemental Impurities in Pharmaceutical Excipients

GANG LI1, DAVE SCHONEKER2,3, KATHERINE L. ULMAN2,3, JASON J. STURM2, LISA M. THACKERY2, JOHN E. KAUFFMAN1

1U.S. Food and Drug Administration, Division of Pharmaceutical Analysis, St. Louis, Missouri 63110
2Colocon Inc., Hatfield, Pennsylvania 19440
3Dow Corning Healthcare Business, Midland, Michigan 48686-0994
4Dow Corning Analytical Sciences, Midland, Michigan 48686-0994
5IPEC-Americas, Arlington, Virginia 22201

Received 14 May 2015; revised 26 August 2015; accepted 28 August 2015
The Problem with Available Data

Data in the literature (such as the FDA study) or that may exist from shared study information is general and not specific to the actual grade and supplier of an excipient used in your particular drug product!

This information may be useful to give the Drug Product manufacturer an idea of what elemental impurities “might” exist in the excipients they use, however, without knowing that the data applies specifically to the grades used, this data is fairly irrelevant for use in a drug product risk assessment!

**Users** must still do appropriate testing of their specific grades or get supplier specific information to properly conduct their risk assessments.

The suppliers of the excipients which were included in the FDA study were provided with the results for their specific samples through the blinding exercise. Therefore, they have some good information about what might be present in the grades they supply.
Limited Supplier EI Information

Some excipient suppliers are fully engaged with this initiative, while others will not engage at all.

This will depend on whether the pharmaceutical uses of the excipient make up a significant share of their business or not – **business potential will drive decisions, not regulatory requirements.**

Many suppliers will only have EI information for elements which may have previously been listed in a compendial monograph or is of interest to their other markets which usually will drive their testing (i.e.; food, electronics, industrial).

Many suppliers **do not** plan to do any additional routine testing for elemental impurities due to ICH Q3D and have no intention of agreeing to any new specifications – although there are some exceptions.

Some suppliers have done some designed studies on a limited number of batches to improve their knowledge of potential EI in their products so they can provide some risk assessment assistance to their customers.
Gathering relevant elemental impurity data
Sharing Information between Makers & Users

An industry “Coalition for the Rational Implementation of Elemental Impurities Requirements” developed a **standardized request letter and form templates** to help facilitate industry communication between users and makers of APIs and excipients. The template was created and designed to help pharmaceutical companies:

- Gather information from suppliers pertaining to potential metals/concentrations (and the potential for excursions) in both APIs and excipients used in the production of drug products.

- Use information from suppliers (when available) to determine potential presence / concentration of each metal in the assessment of a finished drug product Permitted Daily Exposure (PDE) level.

**NOTE:** both API and excipient manufacturers were encouraged to utilize the Information Exchange request template form to **proactively develop** their own product documentation/information.
Sharing Information between Makers & Users

Information Exchange Request Template

**IDEAL WORLD...**
Pro-actively completed by suppliers and sent to users

**REAL WORLD...**
A limited number of suppliers have data or will complete and return the form to users

Download IPEC-Americas Links:

<table>
<thead>
<tr>
<th>Letter</th>
<th>PDE Calculator Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Template</td>
<td>Daily Intake Calculator</td>
</tr>
</tbody>
</table>

©™Trademark of The Dow Chemical Company ("DOW") or an affiliated company of Dow.
A case study for one excipient supplier’s strategy
FDA Analytical Lab Project

FDA Data

Company A Data

Trademark of The Dow Chemical Company ("DOW") or an affiliated company of Dow.
Established/validated equipment and testing strategy

Clearly defined goal of testing
  • Screening for risk assessment or **formal control**

Clearly defined type of digestion
  • **Total metal extraction** or acid leach

Developed understanding for how materials and matrix could affect analysis
  • Dissolved solids, undigested carbon, etc.

Established level of validation/verification needed and completed validation activities

Developed and follow established protocols
  • “sample preparation” and “analysis” methodologies
Developed overall testing and communication strategy

Defined products to test

Trained personnel

Developed base-line elemental impurity levels for each ingredient identified for use in a drug product – where necessary, monitored for excursions

Performed testing

Developed future testing / reporting strategy for each product.

Created and communicated reports to share elemental impurity data for excipient products per USP <232> and ICHQ3D
Current communication strategy

While USP <232> and ICH Q3D are not mandatory for excipients, finished drug manufacturers and authorization holders must assess all sources of elemental impurities in their finished drug product. This letter is intended to provide elemental impurity data for SENTRY™ POLYOX™ Water-Soluble Resins NF grade excipient products per USP <232> and ICH Q3D.

Dow currently performs the following elemental testing on SENTRY™ POLYOX™ Water-Soluble Resins NF products:

- Heavy metals per the USP test method to demonstrate compliance with the USP, PhEur and JP Pharmacopoeia. The USP heavy metals test will give positive indication for the presence of Ag, As, Bi, Cd, Hg, Mo, Pb, Sb, and Sn.

In anticipation of customer requests for Elemental Impurity data per USP <232> and ICH Q3D, Dow has completed an assessment of the manufacturing process and tested representative samples of SENTRY™ POLYOX™ Water-Soluble Resins NF representing all producing plants and production lines for batches produced over a multi-year time period. Conclusions of the manufacturing process assessment are as follows:

ICH Q3D Class I and 2A elements

Risk Assessment considerations
Manufacturing process “Risk” Assessment

- Elemental impurities are not intentionally added to SENTRY™ POLYOX™ products.
- Calcium based catalysts are used in the SENTRY™ POLYOX™ manufacturing process.
- Dow has well-defined manufacturing processes and controls for SENTRY™ POLYOX™ production.
- The reaction vessels are stainless steel clad.

Analytical results for USP <232> and ICH Q3D elemental impurities are summarized in Table I.

- All Class 1 and Class 2A elements were quantified.
- Selenium and Cobalt were added to the USP list for testing due to ICH Q3D requirements.
- No Class 2B elements were intentionally added to Table I, but some Class 2B elements were tested due to USP <232> requirements.
- Chromium and nickel are components of stainless steel. These trace impurities, if present, are from the components of the POLYOX™ manufacturing equipment.

In conclusion, based on the product chemistry, raw materials, materials of construction and the manufacturing processes and controls, as well as results of recent screening tests, SENTRY™ POLYOX™ Water-Soluble Resins NF products do not contain the majority of elemental impurities listed below.
Since the “family” of SENTRY™ POLYOX™ WSR products all utilized the same:

- raw materials
- chemistry
- manufacturing equipment, processing & quality system controls
- packaging materials of construction

Three grades of SENTRY™ POLYOX™ WSR were analyzed to cover the entire FAMILY of POLYOX™ polyethylene oxide.

Equivalent “non-detectable” results were obtained for all three grades.
## Elemental impurity data

<table>
<thead>
<tr>
<th>Elemental Impurity</th>
<th>Class</th>
<th>Likely to be Present</th>
<th>Concentration Units (ppm) ND = Not Detected</th>
<th>Analytical Method Used (and Limit of Detection if Available)</th>
<th>Comments regarding source of information (i.e.: frequency of testing, process understanding, etc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arsenic (inorganic)</td>
<td>As 1</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Cadmium</td>
<td>Cd 1</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Mercury (inorganic)</td>
<td>Hg 1</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Lead</td>
<td>Pb 1</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Cobalt</td>
<td>Co 2A</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Nickel</td>
<td>Ni 2A</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Vanadium</td>
<td>V 2A</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Silver</td>
<td>Ag 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>Not tested</td>
</tr>
<tr>
<td>Gold</td>
<td>Au 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>Not tested</td>
</tr>
<tr>
<td>Indium</td>
<td>Ir 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Osmium</td>
<td>Os 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Palladium</td>
<td>Pd 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Platinum</td>
<td>Pt 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Rhodium</td>
<td>Rh 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Ruthenium</td>
<td>Ru 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Selenium</td>
<td>Se 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Thallium</td>
<td>Ti 2B</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Barium</td>
<td>Ba 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Chromium</td>
<td>Cr 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Copper</td>
<td>Cu 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 0.1 ppm)</td>
</tr>
<tr>
<td>Lithium</td>
<td>Li 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>Not tested</td>
</tr>
<tr>
<td>Molybdenum</td>
<td>Mo 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>Not tested</td>
</tr>
<tr>
<td>Antimony</td>
<td>Sb 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>Not tested</td>
</tr>
<tr>
<td>Tin</td>
<td>Sn 3</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>Not tested</td>
</tr>
<tr>
<td>Aluminum</td>
<td>Al 4</td>
<td>Yes ☐ No ☐</td>
<td>Unknown ☐</td>
<td>ND</td>
<td>&lt;233&gt; Elemental Impurities (LOD 3 ppm)</td>
</tr>
</tbody>
</table>
Conclusions

The level and type of information that excipient suppliers will provide to support drug product risk assessments to meet the ICH Q3D and compendial requirements will vary.

The key to success for both excipient suppliers and drug manufacturers will be for both parties to share information and understand the limitations of what each party may be dealing with.

Often time the dialog is what is most important to ensure that users have enough information to successfully complete their risk assessments.
Acknowledgements

Dave Schoneker, Colorcon
Jeff Pitt, The Dow Chemical Company
Barb Serr, The Dow Chemical Company
Jason Sturm, The Dow Chemical Company
Your Questions – Thank You!
NOTICE: No freedom from infringement of any patent owned by Dow or others is to be inferred. Because use conditions and applicable laws may differ from one location to another and may change with time, Customer is responsible for determining whether products and the information in this document are appropriate for Customer's use and for ensuring that Customer's workplace and disposal practices are in compliance with applicable laws and other government enactments. The product shown in this literature may not be available for sale and/or available in all geographies where Dow is represented. The claims made may not have been approved for use in all countries. Dow assumes no obligation or liability for the information in this document. References to "Dow" or the "Company" mean the Dow legal entity selling the products to Customer unless otherwise expressly noted. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY EXCLUDED.